From the impact of Obamacare to cutting edge research, from biotech buyouts to big pharma court battles, the Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry, and their implications for long-term investors. In this week's edition, the team talks about big pharma patent disputes, stocks that have both popped and plummeted, and companies our analysts will be watching in the coming days.
This Week in Health Care
By Max Macaluso, Brenton Flynn, and Dave Williamson
-
Apr 5, 2013 at 5:03PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The Motley Fool Health-Care Show for Friday April 5th.
Related Articles
Better Buy: Moderna or Novavax?
Buying These 5 Dividend Stocks Can Make You Nearly $33,000 in Passive Income
Why Cellectis' Shares Rose 22.7% This Week
Why Pfizer Stock Is Rising Today While Moderna and Novavax Are Sliding
This Safe Stock Is Dirt Cheap -- and It's Beating the Market
Motley Fool Returns
Market-beating stocks from our award-winning service.
Stock Advisor Returns
331%
331%
S&P 500 Returns
115%
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Cumulative Growth of a $10,000 Investment in Stock Advisor
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.